Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Author:
Funder
Amgen
Astra Zeneca
Bausch Health
Boehringer Ingelheim
Elpen
MSD
Mylan
Novo Nordisk
Sanofi
Servier
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference83 articles.
1. Nomoto H, et al;Omori,2019
2. Pharmacotherapy of type 2 diabetes: an update;Upadhyay;Metabolism.,2018
3. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management;Katsiki;Curr Pharm Des,2017
4. Antidiabetic drugs as antihypertensives: new data on the horizon;Mamakou;Curr Vasc Pharmacol,2017
5. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis;Batzias;J Diabetes Res,2018
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Diabetes and Non‐alcoholic Fatty Liver Disease;Textbook of Diabetes;2024-01-12
2. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved;Clinical Nutrition;2023-12
3. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease;Journal of Diabetes and its Complications;2023-10
4. Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes;Metabolites;2023-04-04
5. Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study;Biomedicines;2023-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3